This article was originally published in FierceBiotech on November 22nd, 2011 by John Carroll
“After the big biotech deal comes the big biotech buzz. And one of the big questions on everyone’s mind after Gilead Sciences ($GILD) announced its $11 billion deal to acquire Pharmasset is, “Who’s next?” Would Inhibitex, Achillion or Idenix be the next biotech to find itself in the cross hairs of a potential suitor? Would these new deals rival Gilead’s willingness to pay 70 times net assets to complete a deal?
Pharmasset ($VRUS), of course, had already established itself as one of the hottest biotechs …”
To read the full article, please visit FierceBiotech.